Peter Gassner: Yes, these were wins with top 20 customers. And they were — yes, they have to be displacing one of the market leaders because people do need an EDC application. And so in both cases, we’re displacing one of the top 2 market leaders there other than Veeva. And then in terms of the deal sizes, I won’t specifically say in that area, but EDC is one of our larger applications. So it would be one of our — these are larger deals. They’re certainly some of our largest deals. Now these will ramp over multiple years because with the EDC application, you start study by study by study. So it’s a commitment for a long-term approach, but the revenue ramps very slowly, actually, slower than most of our applications, that’s the way that goes.
So right now, our — we are progressing faster with EDC than I would have thought. If you would have asked me in ’20 — in the start of 2020, would we be where we are today with EDC, I probably wouldn’t have been as bullish as what’s actually happened. So our focus is going to be extremely on the customer success there because the EDC also is the — it’s the first part of clinical data management. So that’s that’s we’re focused on. We’re really happy with it, and we’re going to be laser-focused on having implementations just be outstanding and improving our product through the feedback of these large customers. We have to do a lot of things there, right? Customer success, staffing and services. It’s a great work to do, but we got to get better all the time.
Tyler Radke: Yes, that’s great to hear. And maybe on Compass, turning to that, it sounded like you made some comments around continuing to optimize the approach there. Could you just give us an update on how that’s tracking relative to plan? And kind of when you’re expecting that revenue ramp and the timing of when we start to see that in the numbers.
Peter Gassner: Yes. At Compass, that’s certainly a marathon. That’s a tough market. You have a very entrenched player there that has some questionable business practices that make it hard. We’re happy with our progress on the product, and we have a smallish set of early adopters. I won’t go into the specific count of customers. As to when we really start to generate momentum in the revenue, it’s going to be low. It’s not going to be next year. It’s a very long-term play. I’m confident in our position in the market and our product strategy. I’m confident that the market needs competition. But that one is going to be a marathon, and you just have to stay tuned for milestones. That’s the thing about great milestones. You don’t actually know when they’re coming, but we’ll let you know when they get here.
Operator: Your next question comes from the line of Stephanie Davis with SVB Securities.
Stephanie Davis: I know we’ve beaten this to death about the risk when we’ve been off of the Salesforce platform, but I thought I’d add to it. Could you walk us through the WIP associated moving off of it. Is this hiring platform engineers? Is this resources that you already have? Or should we think of this as effectively built out as you’ve already had entrants like med tech built on the Vault platform?
Peter Gassner: Yes. Stephanie, I’ll take that one. The main thing to know is that when we build applications on Vault, we’re highly efficient. We’re highly efficient on that. So there’s a lot of work that has gone into the platform. So we don’t see really material incremental investment. And then we’re using much of the parts of the CRM application. We’re just porting over the back end. So for example, we have a very robust iPad client for Veeva CRM. It has all types of functionality into it. We’re not going to rewrite that application at all. So that’s why the investment is just — it’s not material to the rest of Veeva, it’s because of the leverage, both in the existing application footprint, template and code and then the leverage we get from the Vault platform.
